361 related articles for article (PubMed ID: 30665156)
21. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
22. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH
Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel small molecule non-peptidomimetic inhibitor for prolyl oligopeptidase through
Shrivastava A; Srivastava S; Malik R; Alam MM; Shaqiquzamman M; Akhter M
J Biomol Struct Dyn; 2020 Mar; 38(5):1292-1305. PubMed ID: 30929611
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity.
Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S
SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104
[TBL] [Abstract][Full Text] [Related]
25. 3D QSAR pharmacophore modeling, in silico screening, and density functional theory (DFT) approaches for identification of human chymase inhibitors.
Arooj M; Thangapandian S; John S; Hwang S; Park JK; Lee KW
Int J Mol Sci; 2011; 12(12):9236-64. PubMed ID: 22272131
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide.
Racys DT; Rea D; Fülöp V; Wills M
Bioorg Med Chem; 2010 Jul; 18(13):4775-82. PubMed ID: 20627594
[TBL] [Abstract][Full Text] [Related]
27. Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation.
Qiu Y; Zhou L; Hu Y; Bao Y
J Recept Signal Transduct Res; 2019 Apr; 39(2):154-166. PubMed ID: 31355691
[TBL] [Abstract][Full Text] [Related]
28. Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors.
John S; Thangapandian S; Arooj M; Hong JC; Kim KD; Lee KW
BMC Bioinformatics; 2011 Dec; 12 Suppl 14(Suppl 14):S4. PubMed ID: 22372967
[TBL] [Abstract][Full Text] [Related]
29. 3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors.
Kumar V; Parate S; Danishuddin ; Zeb A; Singh P; Lee G; Jung TS; Lee KW; Ha MW
Front Cell Infect Microbiol; 2022; 12():909111. PubMed ID: 35846777
[TBL] [Abstract][Full Text] [Related]
30. In silico screening and study of novel ERK2 inhibitors using 3D QSAR, docking and molecular dynamics.
Larif S; Salem CB; Hmouda H; Bouraoui K
J Mol Graph Model; 2014 Sep; 53():1-12. PubMed ID: 25064438
[TBL] [Abstract][Full Text] [Related]
31. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.
Tarragó T; Masdeu C; Gómez E; Isambert N; Lavilla R; Giralt E
ChemMedChem; 2008 Oct; 3(10):1558-65. PubMed ID: 18792035
[TBL] [Abstract][Full Text] [Related]
32. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
Tripathy S; Azam MA; Jupudi S; Sahu SK
J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
[TBL] [Abstract][Full Text] [Related]
33. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation.
Wu M; Han J; Liu Z; Zhang Y; Huang C; Li J; Li Z
Life Sci; 2020 Oct; 258():118228. PubMed ID: 32781071
[TBL] [Abstract][Full Text] [Related]
34. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
35. Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
Son M; Park C; Rampogu S; Zeb A; Lee KW
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823604
[TBL] [Abstract][Full Text] [Related]
36. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
Zhu J; Wu Y; Xu L; Jin J
Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
[TBL] [Abstract][Full Text] [Related]
37. In silico approaches to evaluate the molecular properties of organophosphate compounds to inhibit acetylcholinesterase activity in housefly.
Marimuthu P; Lee YJ; Kim B; Seo SS
J Biomol Struct Dyn; 2019 Feb; 37(2):307-320. PubMed ID: 29322868
[TBL] [Abstract][Full Text] [Related]
38. Virtual Screening of Novel Glucosamine-6-Phosphate Synthase Inhibitors.
Lather A; Sharma S; Khatkar A
Comb Chem High Throughput Screen; 2018; 21(3):182-193. PubMed ID: 29600755
[TBL] [Abstract][Full Text] [Related]
39. In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer.
Ren JX; Li CP; Zhou XL; Cao XS; Xie Y
J Biomol Struct Dyn; 2018 Jul; 36(9):2424-2435. PubMed ID: 28714799
[TBL] [Abstract][Full Text] [Related]
40. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
